Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1405 plus gemcitabine and cisplatin for first-line advanced triple-negative breast cancer
ChiCTR2000029189Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GR-1405 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
GR-1405
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000029189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029189.